SLC29A1: A Protein as A Drug Target and Biomarker (G2030)

Target Name: SLC29A1

NCBI ID: G2030

SLC29A1

Other Name(s): solute carrier family 29 member 1 (Augustine blood group) | SLC29A1 variant 6 | ENT1 | Equilibrative nucleoside transporter 1 | Equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter | SLC29A1 variant 1 | Equilibrative nucleoside transporter 1 (isoform 4) | Solute carrier family 29 member 1 | solute carrier family 29 (nucleoside transporters), member 1 | Solute carrier family 29, member 1 | S29A1_HUMAN | SLC29A1 variant 4 | Equilibrative NBMPR-sensitive nucleoside transporter | Solute carrier family 29 member 1 (Augustine blood group), transcript variant 1 | Solute carrier family 29 (equilibrative nucleoside transporter), member 1, transcript variant 5 | Solute carrier family 29 member 1 (Augustine blood group), transcript variant 6 | solute carrier family 29 (equilibrative nucleoside transporter), member 1 | equilibrative nitrobenzylmercaptopurine riboside (NBMPR)-sensitive nucleoside transporter | SLC29A1 variant 5 | Solute carrier family 29 (equilibrative nucleoside transporter), member 1 | Solute carrier family 29 (nucleoside transporters), member 1 | Equilibrative nitrobenzylmercaptopurine riboside (NBMPR)-sensitive nucleoside transporter | Equilibrative nucleoside transporter 1 (isoform 1) | nucleoside transporter, es-type | Nucleoside transporter, es-type | Solute carrier family 29 (equilibrative nucleoside transporter), member 1, transcript variant 4 | Equilibrative nucleoside transporter 1 (isoform 5) | Solute carrier family 29 member 1 (SLC29A1, ENT1)

SLC29A1: A Protein as A Drug Target and Biomarker

SLC29A1 is a protein that is expressed in many different tissues throughout the body. It is a member of the SLC29 family, which is a well-known family of transmembrane proteins that play a crucial role in the transport of various substances across cell membranes. One of the unique features of SLC29A1 is its role as a drug target and biomarker, which has significant implications for the development of new treatments for a variety of diseases.

SLC29A1 has been shown to play a key role in the transport of different molecules across cell membranes, including drugs that are used to treat a wide range of conditions. For example, SLC29A1 has been shown to transport many different types of drugs, including proteins, nucleic acids, and lipids. It has also been shown to play a key role in the regulation of intracellular signaling pathways, which are critical for the proper functioning of many different cell processes.

One of the reasons why SLC29A1 is such an attractive drug target is its location on the surface of many different cell types. Because it is expressed in many different tissues, it is possible to target it using a variety of different techniques, which allows researchers to test the effectiveness of different drugs on a wide range of cell types. This is particularly important for the development of new treatments for diseases that affect a large number of different cell types, such as cancer.

In addition to its role as a drug target, SLC29A1 has also been shown to be a valuable biomarker for many different types of diseases. For example, it has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease, as well as in the regulation of inflammation and immune responses. This makes it an attractive target for researchers who are looking for new ways to diagnose and treat these types of diseases.

SLC29A1 is also a potential drug target because of its unique structure and biology. Unlike many other proteins, which are made up of a long sequence of amino acids, SLC29A1 is made up of a single protein that is composed of four distinct subunits. This unique structure allows researchers to study the molecular mechanisms that are responsible for its function, which has important implications for the development of new treatments.

Finally, SLC29A1 is an attractive drug target because of its potential to be a versatile drug. Because it is expressed in many different tissues and can be targeted using a variety of different techniques, it is possible to develop a treatment that targets SLC29A1 in a specific and effective way. This has the potential to revolutionize the field of drug development and improve the treatment outcomes for a wide range of diseases.

In conclusion, SLC29A1 is a protein that has significant implications for the development of new treatments for a variety of diseases. Its role as a drug target and biomarker makes it an attractive target for researchers who are looking for new ways to diagnose and treat a wide range of conditions. Its unique structure and biology also make it a promising target for the development of new drugs that can be effective in a wide range of different cell types.

Protein Name: Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Functions: Bidirectional uniporter involved in the facilitative transport of nucleosides, nucleobases and therapeutic analogs, and contributes to maintaining their cellular homeostasis (PubMed:8986748, PubMed:10755314, PubMed:12527552, PubMed:10722669, PubMed:21795683, PubMed:35790189). Functions as a Na(+)-independent transporter (PubMed:8986748). Involved in the transport of nucleosides such as adenosine, guanosine, inosine, uridine, thymidine and cytidine (PubMed:8986748, PubMed:10755314, PubMed:12527552, PubMed:10722669). Also transports purine nucleobases (hypoxanthine, adenine, guanine) and pyrimidine nucleobases (thymine, uracil) (PubMed:21795683). Mediates basolateral nucleoside uptake into Sertoli cells, thereby regulating the transport of nucleosides in testis across the blood-testis-barrier (PubMed:23639800). Regulates inosine levels in brown adipocytes tissues (BAT) and extracellular inosine levels, which controls BAT-dependent energy expenditure (PubMed:35790189)

The "SLC29A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC29A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets